Nikhil Upadhyay

Congrats on a good set of numbers. 2 questions. If I look at ours -- and one thing I should appreciate is the kind of detail you put in your presentation, it's phenomenal. It gives a very good understanding of where we are going. 1 question on Slide 12, if we look at the API side. If we track over the last 4 quarters, the number of programs in specialty CDMO has increased significantly.

Okay. And second question is a little longer. See, if you look at our company, from 2018 to 2023, '24, we were in an investment phas e in different segments -- Biosimilars, Albumin, and APIs. And we are now seeing the fruits of which over the last 2 years, and this should continue.

Yes, that is one part of the capex. But on the R&D side, where are you putting most of your energy? Because on one side, we have our own specialty 505(b)(2) molecules and specialty molecules where we are d oing clinical trials. And there is another part which is equally interesting, the Biologics CDMO and API CDMO, which is again a strong growth engine for the whole industry.